In the synthesis of research peptides via Fmoc-SPPS, not every coupling step runs to a hundred per cent. A small percentage of amino groups remains unreached, and without intervention those missed couplings accumulate into a mixture of by-products that depresses the eventual purity of the research material. Two mechanisms play a central role here: capping and racemisation. This article describes how they arise, why they matter for the quality of a peptide batch, and how laboratories address them in the synthesis strategy.
What is capping and why is it used?
During every coupling cycle in SPPS an activated amino acid reacts with the free amino group on the growing peptide on the resin. In practice this reaction is never complete: a fraction of the amino groups remains unreacted, usually on the order of a fraction of a per cent per step. For a peptide of twenty or thirty residues, that adds up.
Capping is the step in which these remaining, unreacted amino groups are deliberately blocked — usually with an acetylating reagent such as acetic anhydride. The aim is not to repair the error, but to prevent that unreacted chain from growing further in later cycles. A capped chain stops at that point and becomes physically shorter than the intended end product during synthesis.
How deletion sequences arise
Without capping, an unreacted chain would simply take part in the next coupling round as though nothing had gone wrong. The result is a peptide in which one amino acid is simply missing: a deletion sequence. Because these sequences lie close to the desired product in mass and often in retention time as well, they are notoriously difficult to separate with standard reversed-phase HPLC.
By capping deliberately, a deletion sequence becomes instead a strongly shortened, capped chain. That shorter fragment differs far more in physicochemical terms from the complete peptide, which simplifies separation during purification considerably. Capping therefore moves the problem from “almost impossible to separate” to “relatively easy to remove”.
Racemisation: a second threat to stereochemical purity
Besides deletion, racemisation plays a part in the coupling step itself. During activation of an amino acid an intermediate can form — an oxazolone ring — which via enolisation can invert the stereocentre of the amino acid. The consequence is a D-amino acid at a position where an L-amino acid was intended, producing a diastereomer of the target peptide rather than a deletion or truncation.
This risk is not equal for every amino acid: cysteine and histidine are known to be particularly prone to racemisation during coupling. Additives such as HOBt or OxymaPure, often already present when using coupling reagents like HBTU or HATU, suppress the formation of the racemisation-prone intermediate and keep the proportion of D-amino acid low.
Why this matters for the quality of research material
Deletion sequences and racemisation products are two of the most important sources of impurity in synthetic research peptides, alongside oxidation and other degradation routes that can occur after synthesis. For a researcher assessing a CoA, this explains why purity figures, chromatograms and — where relevant — chiral analysis together give a fuller picture than a single purity percentage. A peptide can look analytically pure by mass while a small proportion of diastereomer is nonetheless present and becomes visible only with targeted techniques.
For laboratories carrying out or assessing peptide synthesis themselves, capping is therefore not an optional step but a fixed part of a robust synthesis protocol, just as the choice of coupling reagent and the orthogonality of protecting groups are.
In closing
Capping and the suppression of racemisation are two of the less visible but essential links between crude synthesis and a usable, well-characterised research peptide. They illustrate that peptide purity is not only a matter of purification afterwards, but equally of choices made during synthesis itself.
This information is intended solely for laboratory and research purposes. The products and information of Dutch Peptide Labs are not intended for human or animal consumption, diagnostic use or therapeutic application.
